At a glance

Cyberonics is celebrating 25 years! Click here to see our progress.

Cyberonics is committed to advancing device-based solutions that improve the lives of patients and their families. Our core beliefs guide us to design, develop and market patient-focused medical device solutions for people affected by epilepsy, depression, and other chronic disorders.

At Cyberonics, more than 530 employees worldwide work passionately to improve the quality of life for patients, their families, and caregivers. Since the first clinical experience in 1988, more than 65,000 patients worldwide have been treated with VNS Therapy.

VNS logo

VNS Therapy is a non-drug treatment option that offers a unique safety profile and mechanism of action. Approved for use in refractory epilepsy and in treatment-resistant depression, VNS Therapy delivers long-term benefits to patients who have not responded well to other treatment options.